Merck & Company, Inc. (MRK) Financial Statements

Merck & Company, Inc.

MRK · NYSE

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$65.01B	$64.17B	$60.12B	$59.28B	$48.70B	$41.52B	$39.12B	$42.29B
Cost of Revenue	$16.38B	$15.19B	$16.13B	$17.41B	$13.63B	$13.62B	$12.02B	$13.51B
Research & Development	$15.79B	$17.94B	$30.53B	$13.55B	$12.24B	$13.40B	$9.72B	$9.75B
Selling, General & Administrative	$10.73B	$10.82B	$10.50B	$10.04B	$9.63B	$8.96B	$9.46B	$10.10B
Interest Expense	—	—	$1.15B	$962.00M	$806.00M	$831.00M	$893.00M	$772.00M
Other Income / (Expense)	-$151.00M	$24.00M	-$466.00M	-$1.50B	$1.34B	$890.00M	-$129.00M	$402.00M
Income Before Taxes	$21.07B	$19.94B	$1.89B	$16.44B	$13.88B	$5.86B	$7.17B	$8.70B
Provision for Income Taxes	$2.80B	$2.80B	$1.51B	$1.92B	$1.52B	$1.34B	$1.56B	$2.51B
Net Income	$18.25B	$17.12B	$365.00M	$14.52B	$12.35B	$7.07B	$9.84B	$6.22B
Basic EPS	$7.30	$6.76	$0.14	$5.73	$5.16	$2.79	$3.84	$2.34
Diluted EPS	$7.28	$6.74	$0.14	$5.71	$5.14	$2.78	$3.81	$2.32
Basic Shares Outstanding	2.50B	2.53B	2.54B	2.53B	2.53B	2.53B	2.56B	2.66B
Diluted Shares Outstanding	2.51B	2.54B	2.55B	2.54B	2.54B	2.54B	2.58B	2.68B

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$2.72	$2.70	$2.73	2	↑0 ↓2
Dec 2027	$9.72	$9.29	$10.06	8	↑1 ↓3
Dec 2028	$11.06	$10.89	$11.26	3	↑1 ↓0
Dec 2029	$12.27	$12.27	$12.27	1	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: MRK
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Key Issues

Bullish view

Strong oncology performance and newer products helped Merck beat second-quarter estimates, while the company raised and narrowed its 2026 sales outlook.

Bearish view

The evidence also flags Gardasil challenges and Keytruda-related concerns, so current oncology strength may not fully offset weakness elsewhere in the portfolio.

Analyst Consensus

See all

Buy

24 analysts

$129

Current

—

Low

$137

Average

—

High

Average target implies +6.23% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Novartis AGNVS · NYSE$154.50